Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPA-FFA in Hospitalized COVID-19
NCT04335032Phase 3Unknown
- Sponsor
- SLA Pharma
- Start
- Jan 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of EPAspire in coronavirus disease 2019 (COVID-19), sponsored by SLA Pharma. Status: unknown.
02
Drugs
EPAspire
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04335032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04335032.